Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
Purpose
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Conditions
- Intracerebral Hemorrhage
- Atrial Fibrillation
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Age at least 18 years - Intracerebral hemorrhage (ICH) (including primary intraventricular hemorrhage) confirmed by brain CT or MRI - Can be randomized within 14-180 days after ICH onset - Non-valvular AF (defined as atrial fibrillation or atrial flutter), documented by electrocardiography or a physician-confirmed history of prior AF - Provision of signed and dated informed consent form by patient or legally authorized representative - For females of reproductive potential: use of highly effective contraception
Exclusion Criteria
- Index event is hemorrhagic transformation of a brain infarction or hemorrhage into a tumor - History of earlier ICH within 12 months preceding index event - Active infective endocarditis - Clear indication for anticoagulant drugs (e.g., requires anticoagulation for deep vein thrombosis or pulmonary embolism) or antiplatelet drugs (e.g., requires aspirin or clopidogrel for recent coronary stent). - Previous or planned left atrial appendage closure - Clinically significant bleeding diathesis - Serum creatinine ≥2.5 mg/dL - Active hepatitis or hepatic insufficiency with Child-Pugh score B or C - Anemia (hemoglobin <8 g/dL) or thrombocytopenia (<100 x 10^9/L) that is chronic in the judgment of the investigator - Pregnant or breastfeeding - Known allergy to aspirin or apixaban - Concomitant participation in a competing trial - Considered by the investigator to have a condition that precludes safe or active participation in the trial - Persistent, uncontrolled systolic blood pressure (≥180 mm Hg) - ICH caused by an arteriovenous malformation (AVM) that has not yet been secured
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Prevention
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Active Comparator Apixaban |
Apixaban dosing will be 5 mg tablet in morning and 5 mg tablet in evening. A reduced dose of 2.5 mg tablet in morning and 2.5 mg tablet in evening will be used if: (1) ≥2 of the following are present: age ≥80 years, body weight ≤60 kg, or serum creatinine 1.5-2.4 mg/dL, or (2) Patient is taking a strong CYP3A4/pGP inhibitor (e.g., ketoconazole, itraconazole, ritonavir, or clarithromycin). |
|
Placebo Comparator Aspirin |
Aspirin dose will be 81 mg tablet once daily. |
|
Recruiting Locations
Birmingham, Alabama 35294
Angela Shapshak, MD
Mobile, Alabama 36604
Taha Nisar, MD
Tucson, Arizona 85719
Firas Kaddouh, MD
Carmichael, California 95608
Lucian Maidan
Colton, California 92324
Dan Miulli, MD
Fontana, California 92335
Vaninder Chhabra
Los Alamitos, California 90720
Nirav Patel, MD
Los Angeles, California 90027
Harsimran Brara, MD
Los Angeles, California 90048
Konrad Schlick, MD
Los Angeles, California 90095
Latisha Sharma, MD
Modesto, California 95350
James Jaffe, MD
Orange, California 92868
Wengui Yu, MD
Palm Springs, California 92262
Kevin Attenhofer, MD
Pasadena, California 91105
Arib Ohanian, MD
Redwood City, California 94063
Sheila Chan, MD
Sacramento, California 95817
Kwan Ng, MD
Sacramento, California 95825
Yekaterina Axelrod, MD
San Francisco, California 94110
Claude Hemphill, MD
Stanford, California 94304
Chitra Venkat, MD
Whittier, California 90602
Gautam Ganguly, MD
Danbury, Connecticut 06810
Charles Guardia, MD
Hartford, Connecticut 06102
Mark Alberts, MD
New Haven, Connecticut 06511
Guido Falcone, MD
Wilmington, Delaware 28403
James McKinney, MD
Washington, District of Columbia 20007
Douglas Mayson, MD
Clearwater, Florida 33756
Ajay Arora, MD
Miami, Florida 33136
Sebastian Koch
Pensacola, Florida 32504
Terry Neill, MD
Port Saint Lucie, Florida 34987
Marc Babi, MD
Tampa, Florida 33606
Swetha Renati, MD
Tampa, Florida 33607
Abilash Haridas, MD
Atlanta, Georgia 30303
Daniel Schachter, MD
Atlanta, Georgia 30322
Fadi Nahab, MD
Augusta, Georgia 30912
Fenwick Nichols, MD
Marietta, Georgia 30060
Christopher Horn, MD
Honolulu, Hawaii 96813
Kazuma Nakagawa, MD
Chicago, Illinois 60612
Rima Dafer, MD
Chicago, Illinois 60612
Ali Alaraj, MD
Chicago, Illinois 60637
Elisheva Coleman, MD
Maywood, Illinois 60153
Sarkis Morales-Vidal, MD
Peoria, Illinois 61637
Arun Talkad
Winfield, Illinois 60190
Dhruvil Pandya, MD
Iowa City, Iowa 52242
Amir Shaban, MD
Kansas City, Kansas 66160
Kyle Carpenter, MD
Lexington, Kentucky 40536
Suhas Gangadhara, MD
New Orleans, Louisiana 70121
Richard Zweifler
Boston, Massachusetts 02111
Emiliya Melkumova, MD
Boston, Massachusetts 02114
Mariel Kozberg, MD
Boston, Massachusetts 02118
Steven Feske, MD
Boston, Massachusetts 02215
Magdy Selim, MD
Burlington, Massachusetts 01805
Colin James Culbertson, MD
Springfield, Massachusetts 01199
Gottfried Schlaug, MD
Worcester, Massachusetts 01655
Majaz Moonis, MD
Ann Arbor, Michigan 48109
Aditya Pandey
Flint, Michigan 48532
Bharath Naravetla, MD
Grand Rapids, Michigan 49503
Muhammad Farooq, MD
Mount Clemens, Michigan 48043
Bharath Naravetla, MD
Traverse City, Michigan 49684
David Rosenbaum, MD
Minneapolis, Minnesota 55407
Ganesh Asaithambi, MD
Minneapolis, Minnesota 55455
Oladi Bentho, MD
Saint Cloud, Minnesota 56303
Muhammad Fareed Suri, MD
Saint Louis Park, Minnesota 55426
Darwin Ramirez Abreu, MD
Saint Paul, Minnesota 55101
Darwin Ramirez-Abreu, MD
Jackson, Mississippi 39216
Allison Strickland, MD
Saint Louis, Missouri 63110
Yan Wang, MD
Springfield, Missouri 65807
Benjamin Lisle, MD
Omaha, Nebraska 68105
Marco Gonzalez Castellon, MD
Summit, New Jersey 07901
John Hanna, MD
Albuquerque, New Mexico 87106
Tarun Girotra, MD
Bronx, New York 10467
Kathryn Kirchoff-Torres, MD
Brooklyn, New York 11203
Susan Law, MD
Brooklyn, New York 11219
Quingliang Wang, MD
Brooklyn, New York 11220
Jennifer Frontera
Manhasset, New York 11030
Rohan Arora, MD
New York, New York 10019
Neha Dangayach, MD
New York, New York 10029
Neha Dangayach, MD
New York, New York 10032
Imama Naqvi, MD
New York, New York 10065
Hooman Kamel, MD
Poughkeepsie, New York 12601
Paul Wright, MD
Rochester, New York 14642
Curtis Benesch, MD
Stony Brook, New York 11794
Jason Mathew, MD
Syracuse, New York 13210
Julius-Gene Latorre, MD
Valhalla, New York 10595
Stephan Mayer, MD
Chapel Hill, North Carolina 27514
David Huang, MD
Winston-Salem, North Carolina 27103
Lauren Peruski, MD
Winston-Salem, North Carolina 27157
Stacey Wolfe, MD
Akron, Ohio 44307
Ahmed Itrat, MD
Cincinnati, Ohio 45219
Rob Stanton, MD
Cincinnati, Ohio 45220
Christopher Zammit, MD
Cleveland, Ohio 44106
Abhishek Ray, MD
Cleveland, Ohio 44109
Agnieszka Ardelt, MD
Cleveland, Ohio 44195
Blake Buletko
Columbus, Ohio 43210
Yousef Hannawi, MD
Columbus, Ohio 43214
Vivek Rai, MD
Oklahoma City, Oklahoma 73104
Evgeny Sidorov
Tulsa, Oklahoma 74104
Rahul Rahangdale, MD
Tulsa, Oklahoma 74104
Rahul Rahangdale, MD
Portland, Oregon 92739
Wayne Clark
Portland, Oregon 97213
John Zurasky
Springfield, Oregon 97477
Elaine Skalabrin, MD
Abington, Pennsylvania 19001
Larami MacKenzie, MD
Danville, Pennsylvania 17822
Clemens Schirmer, MD
Hershey, Pennsylvania 17033
Nandakumar Nagaraja, MD
Philadelphia, Pennsylvania 19104
Jens Witsch, MD
Philadelphia, Pennsylvania 19107
Diana Tzeng, MD
Philadelphia, Pennsylvania 19140
Paul Katz, MD
Pittsburgh, Pennsylvania 15213
Marcelo Rocha
Providence, Rhode Island 02903
Torrey Birch, MD
Charleston, South Carolina 29425
Christine Holmstedt, MD
Greenville, South Carolina 29605
Sanjeev Sivakumar, MD
Sioux Falls, South Dakota 57108
Jonathon Cooke, MD
Chattanooga, Tennessee 37403
Mounzer Kassab, MD
Knoxville, Tennessee 37916
S. Arthur Moore, MD
Memphis, Tennessee 38104
Balaji Krishnaiah, MD
Nashville, Tennessee 37232
Deborah Kerrigan, MD
Houston, Texas 77030
Britz Britz, MD
Houston, Texas 77030
Andrew Barreto, MD
San Antonio, Texas 78229
Reza Behrouz, MD
Salt Lake City, Utah 84112
Nabeel Chauhan, MD
Burlington, Vermont 05401
Chris Commichau
Charlottesville, Virginia 22908
Brad Worral, MD
Falls Church, Virginia 22042
Saqib Chaudhry, MD
Richmond, Virginia 23298
Shraddha Mainali, MD
Seattle, Washington 98104
David Tirschwell, MD
Seattle, Washington 98122
James Bartscher, MD
Morgantown, West Virginia 26506
Amelia Adcock, MD
Milwaukee, Wisconsin 53226
Hatim Attar, MD
More Details
- NCT ID
- NCT03907046
- Status
- Recruiting
- Sponsor
- Yale University
Detailed Description
ASPIRE is a randomized, double-blinded, phase III clinical trial designed to test the efficacy and safety of anticoagulation, compared with aspirin, in patients with a recent ICH and non-valvular AF. Seven hundred patients will be enrolled over 3.5 years and followed for study outcomes for a minimum of 12 months and maximum of 36 months. The primary efficacy outcome is any stroke (hemorrhagic or ischemic) or death from any cause. The secondary efficacy outcome is the change in the modified Rankin Scale score. Recruitment will take place at sites coordinated through the NIH/NINDS StrokeNet.